Pink SheetThe European Medicines Agency is this week deciding whether to recommend pan-EU marketing authorization for a number of new medicines, including obecabtagene autoleucel (obe-cel), Autolus Therapeutics
ScripNovartis will bolster its neurodegeneration pipeline and specifically its Huntington’s disease portfolio in a license-and-collaboration deal with PTC Therapeutics announced on 2 December that analysts
Scrip$825m looks like a lot to spend acquiring a drug that only sold €72m ($79m) in 2023, but sales of Sanofi ’s Enjaymo are forecast to grow fast, and Recordati SpA has pounced on it. The asset is the
ScripMajority shareholder CVC Capital Partners may be weighing up the sale of its stake in Recordati SpA but it is business as usual at the Italian pharmaceutical company which has posted a decent set of